Amgen Inc. (formerly Applied Molecular Genetics Inc.) is a multinational biopharmaceutical company. The Company's largest selling product lines are Neulasta/Neupogen, two closely related drugs used to prevent infections in patients undergoing cancer chemotherapy; and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.
Type
Public
HQ
Thousand Oaks, US
Founded
1980
Size (employees)
20,800 (est)+9%
Website
amgen.com
Amgen was founded in 1980 and is headquartered in Thousand Oaks, US
Report incorrect company information

Key People/Management at Amgen

Robert Bradway

Robert Bradway

Chairman and Chief Executive Officer
Suzanne Blaug

Suzanne Blaug

SVP, Global Marketing and Commercial Development

Amgen Office Locations

Amgen has offices in Singapore, Jersey City, Thousand Oaks, San Francisco and in 58 other locations
Thousand Oaks, US (HQ)
One Amgen Center Drive
Show all (62)
Report incorrect company information

Amgen Financials and Metrics

Amgen Financials

Amgen's revenue was reported to be $22.99 b in FY, 2016 which is a 6.1% increase from the previous period.
USD

Revenue (Q1, 2018)

5.6 b

Gross profit (Q1, 2018)

4.6 b

Gross profit margin (Q1, 2018), %

83%

Net income (Q1, 2018)

2.3 b

EBIT (Q1, 2018)

2.7 b

Market capitalization (15-May-2018)

114 b

Closing share price (15-May-2018)

172.3

Cash (31-Mar-2018)

9.7 b

EV

139.8 b
Amgen's current market capitalization is $114 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

18.7 b20.1 b21.7 b23 b

Revenue growth, %

7%8%6%

Cost of goods sold

3.3 b4.4 b4.2 b4.2 b

Gross profit

15.3 b15.6 b17.4 b18.8 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

4.7 b4.5 b5.2 b5 b5 b5.4 b5.7 b5.5 b5.7 b5.8 b5.5 b5.8 b5.8 b5.6 b

Cost of goods sold

788 m1.1 b1.1 b1.1 b1 b1.1 b1 b1 b1.1 b1 b996 m1 b990 m944 m

Gross profit

4 b3.4 b4.1 b4 b4 b4.3 b4.7 b4.5 b4.6 b4.8 b4.5 b4.8 b4.8 b4.6 b

Gross profit Margin, %

83%76%79%79%79%80%82%82%82%82%82%82%83%83%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.8 b3.7 b4.1 b3.2 b

Accounts Receivable

2.7 b2.5 b3 b3.2 b

Inventories

3 b2.6 b2.4 b2.7 b

Current Assets

27.4 b34.7 b38.5 b46 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

8.3 b3.7 b4.4 b3.7 b2.9 b3.8 b3.2 b2.9 b2.6 b3.5 b3.4 b2.6 b3 b9.7 b

Accounts Receivable

2.7 b2.5 b2.7 b2.4 b2.5 b2.8 b2.9 b3.1 b3.1 b3.2 b3.2 b3.6 b3.4 b3.6 b

Inventories

2.8 b3 b3 b2.9 b2.7 b2.6 b2.5 b2.6 b2.7 b2.7 b2.9 b3 b2.9 b3 b

Current Assets

30.7 b28.3 b34.3 b36 b35.1 b37.7 b38.8 b42.2 b42.9 b45.8 b46.5 b48.4 b49.8 b40.7 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

5.1 b5.2 b6.9 b7.7 b

Inventories

(7 m)327 m481 m(80 m)

Accounts Payable

(184 m)405 m(12 m)(44 m)

Cash From Operating Activities

6.3 b8.6 b9.1 b10.4 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q1, 2018

Net Income

1.4 b1.1 b1.5 b1.2 b1.6 b2.3 b

Depreciation and Amortization

471 m

Inventories

(107 m)

Accounts Payable

(278 m)
USDY, 2018

EV/EBIT

51.3 x

EV/CFO

51.3 x

Financial Leverage

4.6 x
Show all financial metrics
Report incorrect company information

Amgen News and Updates

The FDA just approved the first drug designed to prevent migraines

The drug is called Aimovig and is made by pharmaceutical giants Amgen and Novartis. The drug is called Aimovig and is made by pharmaceutical giants Amgen and Novartis. It is delivered via injection with a device that is similar to an insulin pen, reports the New York Times. Aimovig works by blocking…

UPDATE 4-U.S. FDA approves Amgen drug for prevention of migraines

May 17 (Reuters) - Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults.

CORRECTED-UPDATE 3-U.S. FDA approves Amgen drug for prevention of migraines

May 17 (Reuters) - Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults.

UPDATE 2-U.S. FDA approves Amgen drug for prevention of migraines

May 17 (Reuters) - Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug to prevent migraine headaches in adults.

UPDATE 1-U.S. FDA approves Amgen drug for prevention of migraines

May 17 (Reuters) - Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug to prevent migraine headaches in adults.

The FDA just approved a new kind of medication that could change the way we treat a condition that affects 38 million Americans

The FDA just approved a new preventative migraine treatment.  The drug, Aimovig, is the first of a new class of medications that's going after the huge migraine market.   An estimated 38 million Americans have migraines and around a third of those people would be eligible for preventive treatment.…
Show more
Report incorrect company information